NDLI: Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.

Please wait, while we are loading the content...

Trends in leisure time physical activity, smoking, body mass index and alcohol consumption in Danish adults with and without diabetes: a repeat cross-sectional national survey covering the years 2000 to 2010.

Prevalence and predictors of postpartum glucose intolerance in Italian women with gestational diabetes mellitus.

Relationships between adipokines, biomarkers of endothelial function and inflammation and risk of type 2 diabetes.

Differential patterns of effects of age and sex on metabolic syndrome in Taiwan: implication for the inadequate internal consistency of the current criteria.

Predictors of hyperglycaemic individuals who do not follow up with physicians after screening in Japan: a cohort study.

Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.

Use of antidepressants and statins and short-term risk of new-onset diabetes among high risk adults.

Year: 2014 Volume: 105 Issue: 1

Year: 2014 Volume: 104

Year: 2014 Volume: 103

Year: 2013 Volume: 102

Year: 2013 Volume: 101

Year: 2013 Volume: 100

Year: 2013 Volume: 99

Year: 2012 Volume: 98

Year: 2012 Volume: 97

Year: 2012 Volume: 96

Year: 2012 Volume: 95

Year: 2011 Volume: 94

Year: 2011 Volume: 93

Year: 2011 Volume: 92

Year: 2011 Volume: 91

Year: 2010 Volume: 90

Year: 2010 Volume: 89

Year: 2010 Volume: 88

Year: 2010 Volume: 87

Year: 2009 Volume: 86

Year: 2009 Volume: 85

Year: 2009 Volume: 84

Year: 2009 Volume: 83

Year: 2008 Volume: 82

Year: 2008 Volume: 81

Year: 2008 Volume: 80

Year: 2008 Volume: 79

Year: 2007 Volume: 78

Year: 2007 Volume: 77

Year: 2007 Volume: 76

Year: 2006 Volume: 72

Year: 2006 Volume: 71

Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Sjöstrand, Mikaela Iqbal, Nayyar Lu, Jane Hirshberg, Boaz
Description	Author Affiliation: Sjöstrand M ( AstraZeneca, Mölndal, Sweden. Electronic address: mikaela.sjostrand@astrazeneca.com.); Iqbal N ( Bristol-Myers Squibb, Princeton, NJ, USA.); Lu J ( AstraZeneca, Wilmington, DE, USA.); Hirshberg B ( AstraZeneca, Wilmington, DE, USA.)
Abstract	AIMS: Saxagliptin reduced glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), and postprandial glucose (PPG) in Asian patients with type 2 diabetes mellitus (T2DM). To understand the physiology of this effect, indices of - and ß-cell function were measured in a subpopulation of Chinese patients following a noodle mixed-meal tolerance test. METHODS: Data from Chinese patients were pooled from two phase 3, 24-week studies of saxagliptin 5mg/d as monotherapy in drug-naive patients and as add-on to metformin in patients inadequately controlled with metformin alone. The end points for ß- and -cell function were change from baseline in C-peptide, insulin, and glucagon areas under the curve from 0 to 180 min (AUC0-180), insulinogenic index, and insulin sensitivity from Matsuda index after a mixed meal. Also glycemic variables, HbA1c, FPG, and PPG (AUC0-180), and homeostasis model assessment (HOMA) 2ß were measured. RESULTS: At 24 weeks, greater improvements in adjusted mean change from baseline HbA1c (difference vs placebo [95% CI], -0.33% [-0.50%, -0.17%], [-4 (-5.5, -1.9) mmol/mol], P<0.0001), FPG (-0.41 [-0.78, -0.03] mmol/L, P=0.03), PPG AUC0-180 (-168 [-245, -91.8] mmol min/L, P<0.0001), C-peptide AUC0-180 (19.7 [5.2, 34.2] nmol min/L, P=0.008), insulinogenic index (0.06% [0.02%, 0.09%], P=0.002), and greater suppression of glucagon secretion (glucagon AUC0-180, -322 [-493.6, -150.7] pmol min/L, P=0.0003) were observed with saxagliptin versus placebo. CONCLUSION: In Chinese patients with T2DM, saxagliptin as monotherapy or as add-on to metformin improved glycemic control by modulating - and ß-cell function.
File Format	HTM / HTML
ISSN	01688227
Issue Number	2
Volume Number	105
e-ISSN	18728227
Journal	Diabetes Research and Clinical Practice
Language	English
Publisher	Elsevier
Publisher Date	2014-08-01
Publisher Place	Ireland
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Research Support, Non-u.s. Gov't Comparative Study Adamantane Glucagon Humans Middle Aged Double-blind Method Male Blood Journal Article Dipeptidyl-peptidase Iv Inhibitors Hypoglycemic Agents Postprandial Period Female Diabetes Mellitus, Type 2 Physiology Drug Therapy, Combination Fasting Hemoglobin A, Glycosylated Drug Therapy Insulin Resistance Blood Glucose Insulin-secreting Cells Metabolism Randomized Controlled Trial Drug Effects Insulin Therapeutic Use Asian Continental Ancestry Group Discipline Endocrinology Analysis C-peptide Dipeptides Multicenter Study Metformin Analogs & Derivatives
Content Type	Text
Resource Type	Article
Subject	Endocrinology, Diabetes and Metabolism Internal Medicine Endocrinology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Metformin + saxagliptin for type 2 diabetes.

Saxagliptin efficacy.

Impact of treatment with saxagliptin on glycaemic stability and ß-cell function in the SAVOR-TIMI 53 study.

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.

Inkretintengelyen ható gyógyszerek a 2-es típusú diabetes kezelésében.

Effect of initial combination therapy with sitagliptin and metformin on ß-cell function in patients with type 2 diabetes.

Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, ß-cell function and insulin resistance in type 2 diabetic patients.

Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.

Similar Documents

Metformin + saxagliptin for type 2 diabetes.

Saxagliptin efficacy.

Impact of treatment with saxagliptin on glycaemic stability and ß-cell function in the SAVOR-TIMI 53 study.

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.

Inkretintengelyen ható gyógyszerek a 2-es típusú diabetes kezelésében.

Effect of initial combination therapy with sitagliptin and metformin on ß-cell function in patients with type 2 diabetes.

Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, ß-cell function and insulin resistance in type 2 diabetic patients.

Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.